Novavax Stock Plunges On Report That Covid Vaccine Is Facing Delays In Europe

Novavax (NVAX) is reportedly struggling to access the raw materials it needs to produce its Covid vaccine, according to a report that sent NVAX stock stumbling Thursday.




X



Supply talks in Europe have stalled, according to Reuters. Earlier this year, the European Union signed a deal for at least 100 million doses of the Novavax vaccine, with an option to buy another 100 million.

The vaccine isn’t yet authorized anywhere. But Novavax says it has begun rolling reviews in the U.K., Europe, Canada, Australia and New Zealand. It’s also in talks with the U.S. Food and Drug Administration through an open application.

In afternoon trading on the stock market today, NVAX stock toppled 15.5% near 169.20.

NVAX Stock Topples On Reports Of Delay

Novavax’s Covid vaccine has proved highly effective in clinical testing. Test results show it’s 96.4% effective against symptomatic cases of Covid-19 caused by the original strain. That’s helped boost NVAX stock this year.

That puts Novavax’s drug among the top performers. Pfizer (PFE) and BioNTech (BNTX) say their drug was 95% effective in Phase 3 testing. Moderna‘s (MRNA) vaccine was 94.1% effective.

But, if authorized, the vaccine would be Novavax’s first commercial product. A Novavax spokeswoman told Reuters the company is working “through some pandemic-related raw-materials supply shortage,” but didn’t give further details.

A Novavax representative didn’t immediately return a request for comment from Investor’s Business Daily.

On a year-to-date basis, NVAX stock has climbed more than 53% on enthusiasm for its vaccine. Shares also have a perfect Relative Strength Rating of 99, reflecting its top-notch performance over the past 12 months, according to IBD Digital.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

YOU MAY ALSO LIKE:

AstraZeneca’s Covid-19 Vaccine Saga Continues With A New Analysis

Is It Time To Buy AbbVie Stock — Or Will Pfizer’s Bad News Continue To Hurt?

Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Find Winning Stocks With MarketSmith Pattern Recognition & Custom Screens